Relypsa (RLYP): Veltassa's Path To Preferred Hyperkalemia Treatment - Wedbush
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Relypsa's (RLYP) Veltassa Expected to Benefit from Delay to AstraZeneca's (AZN) ZS-9 - BTIG
June 2, 2016 7:47 AM EDTBTIG affirms Relypsa (Nasdaq: RLYP) at Buy with a price target of $35 following recent conversations with management.
Analyst Timothy Chiang commented, We recently hosted a Q&A session with Relypsas senior management team to discuss a number of key items including the recent CRL... More
Mizuho Securities Upgrades Relypsa (RLYP) to Neutral; Strengthened Veltassa Launch and Higher Probability of a Takeout
June 1, 2016 6:18 AM EDTMizuho Securities upgraded Relypsa, Inc. (NASDAQ: RLYP) from Underperform to Neutral with a price target of $20.00 (from $12.00).
Analyst Irina Koffler commented, "Relypsa's stock is benefiting from a regulatory delay of competitor AZN, which gives Relypsa more time to strengthen its Veltassa launch and explore strategic alternatives. With the recent run-up, we believe shares are fairly valued and upgrade the stock to Neutral from... More
